In progressive myoclonic epilepsy (PME), controlling myoclonic seizures is a central treatment goal. When the first-line approach fails to achieve that goal, a defined next-line protocol applies.
Valproate is the established first-choice agent for myoclonic seizures in PME. This protocol is indicated when valproate has not achieved the primary goal of reduction or elimination of myoclonic seizures.
After valproate failure, the evidence-based protocol involves specific anticonvulsant agents with documented efficacy in myoclonic seizures — agents whose role in this setting is distinct from valproate. The full structured regimen is available in the complete protocol.